{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:32:06Z","timestamp":1789061526831,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novar"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40123-025-01270-4","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:12:08Z","timestamp":1762920728000},"page":"253-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["One-Year Efficacy and Tolerance of Myofix Defocus Spectacles for Control of Myopia Progression"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct07092072","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rafael","family":"Iribarren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Szeps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kotlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"de Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Rozema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-787X","authenticated-orcid":false,"given":"Carla","family":"Lanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"1270_CR1","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/bjophthalmol-2015-307724","volume":"100","author":"AR Rudnicka","year":"2016","unstructured":"Rudnicka AR, Kapetanakis VV, Wathern AK, Logan NS, Gilmartin B, Whincup PH, et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention. Br J Ophthalmol. 2016;100:882\u201390.","journal-title":"Br J Ophthalmol"},{"key":"1270_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2004.06.004","volume":"24","author":"I Morgan","year":"2005","unstructured":"Morgan I, Rose K. How genetic is school myopia? Prog Retin Eye Res. 2005;24:1\u201338.","journal-title":"Prog Retin Eye Res"},{"key":"1270_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/opo.12040","volume":"33","author":"IG Morgan","year":"2013","unstructured":"Morgan IG, Rose KA. Myopia and international educational performance. Ophthalmic Physiol Opt. 2013;33:329\u201338.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1270_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/bjo.85.7.855","volume":"85","author":"SM Saw","year":"2001","unstructured":"Saw SM, Wu HM, Seet B, Wong TY, Yap E, Chia KS, et al. Academic achievement, close up work parameters, and myopia in Singapore military conscripts. Br J Ophthalmol. 2001;85:855\u201360.","journal-title":"Br J Ophthalmol"},{"key":"1270_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036\u201342.","journal-title":"Ophthalmology"},{"key":"1270_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.62.5.2","volume":"62","author":"P Sankaridurg","year":"2021","unstructured":"Sankaridurg P, Tahhan N, Kandel H, Naduvilath T, Zou H, Frick KD, et al. IMI impact of myopia. Invest Ophthalmol Vis Sci. 2021;62:2.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1270_CR7","volume":"55","author":"W Pan","year":"2025","unstructured":"Pan W, Saw SM, Wong TY, Morgan I, Yang Z, Lan W. Prevalence and temporal trends in myopia and high myopia children in China: a systematic review and meta-analysis with projections from 2020 to 2050. Lancet Reg Health West Pac. 2025;55:101484.","journal-title":"Lancet Reg Health West Pac"},{"key":"1270_CR8","first-page":"68","volume":"31","author":"VIR Sanchez","year":"2016","unstructured":"Sanchez VIR, Latino SG, Torres VE, Gramajo AL, Artal ME, Yadarola MB, et al. Prevalence of refractive errors in Villa Maria, C\u00f3rdoba, Argentina. Eye Sci. 2016;31:68\u201377.","journal-title":"Eye Sci"},{"key":"1270_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/09286580902737524","volume":"16","author":"SA Schellini","year":"2009","unstructured":"Schellini SA, Durkin SR, Hoyama E, Hirai F, Cordeiro R, Casson RJ, et al. Prevalence of refractive errors in a Brazilian population: the Botucatu eye study. Ophthalmic Epidemiol. 2009;16:90\u20137.","journal-title":"Ophthalmic Epidemiol"},{"key":"1270_CR10","first-page":"735","volume":"81","author":"PJ Franco","year":"2021","unstructured":"Franco PJ, Suwezda A, Schlottmann P, Destefanis MP, Rosenstein RE, Iribarren R, et al. Analysis of visual disability in Buenos Aires, Argentina. Pathologic myopia is the leading cause in working age. Medicina (Kaunas). 2021;81:735\u201341.","journal-title":"Medicina (Kaunas)"},{"key":"1270_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.5.5","volume":"62","author":"K Ohno-Matsui","year":"2021","unstructured":"Ohno-Matsui K, Wu PC, Yamashiro K, Vutipongsatorn K, Fang Y, Cheung CMG, et al. IMI pathologic myopia. Invest Ophthalmol Vis Sci. 2021;62:5.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1270_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/ICL.0b013e31824ccbc3","volume":"38","author":"D Jones","year":"2012","unstructured":"Jones D, Luensmann D. The prevalence and impact of high myopia. Eye Contact Lens. 2012;38:188\u201396.","journal-title":"Eye Contact Lens"},{"key":"1270_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/09286580701755560","volume":"15","author":"MF Cortinez","year":"2008","unstructured":"Cortinez MF, Chiappe JP, Iribarren R. Prevalence of refractive errors in a population of office-workers in Buenos Aires, Argentina. Ophthalmic Epidemiol. 2008;15:10\u20136.","journal-title":"Ophthalmic Epidemiol"},{"key":"1270_CR14","doi-asserted-by":"publisher","first-page":"M106","DOI":"10.1167\/iovs.18-25958","volume":"60","author":"CF Wildsoet","year":"2019","unstructured":"Wildsoet CF, Chia A, Cho P, Guggenheim JA, Polling JR, Read S, et al. IMI - Interventions Myopia Institute: interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci. 2019;60:M106\u201331.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1270_CR15","unstructured":"Galan MM SA, Fernandez Irigaray L, Rodriguez G, Aguirre R, Kotlik C, Iribarren R. Myopia Consensus. Oftalmologia Clinica y Experimental 2022; 15. https:\/\/revistaoce.com\/index.php\/revista\/article\/view\/160\/247."},{"key":"1270_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4103\/ijo.IJO_1457_18","volume":"67","author":"SS Kesarwani","year":"2019","unstructured":"Kesarwani SS. Consensus statement and guidelines for use of dilute atropine sulphate in myopia control. Indian J Ophthalmol. 2019;67:461\u20133.","journal-title":"Indian J Ophthalmol"},{"key":"1270_CR17","unstructured":"WSPOS. Myopia Consensus Statement 2023. 2023."},{"key":"1270_CR18","doi-asserted-by":"publisher","first-page":"xi","DOI":"10.1016\/j.ajo.2024.02.027","volume":"263","author":"C Lanca","year":"2024","unstructured":"Lanca C, Pan CW, Grzybowski A. Anti-myopia Spectacles: The Standard of Care in the Future? Ame J Ophthalmol. 2024;263:xi\u2013xiii.","journal-title":"Ame J Ophthalmol"},{"key":"1270_CR19","doi-asserted-by":"publisher","first-page":"M1","DOI":"10.1167\/iovs.18-25980","volume":"60","author":"JS Wolffsohn","year":"2019","unstructured":"Wolffsohn JS, Flitcroft DI, Gifford KL, Jong M, Jones L, Klaver CCW, et al. IMI - myopia control reports overview and introduction. Invest Ophthalmol Vis Sci. 2019;60:M1\u201319.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1270_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1475-1313.2010.00746.x","volume":"30","author":"WN Charman","year":"2010","unstructured":"Charman WN, Radhakrishnan H. Peripheral refraction and the development of refractive error: a review. Ophthalmic Physiol Opt. 2010;30:321\u201338.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1270_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.70313\/2718.7446.v17.n03.350","volume":"17","author":"AKC Szeps","year":"2024","unstructured":"Szeps AKC, Fern\u00e1ndez Irigaray L, Saracco G, De Tomas M, Martin G, Iribarren R. Baseline data in the study on the tolerance and efficacy of peripheral defocus spectacles for the control of myopia progression in Argentina (Myofix Defocus Study). Oftalmol Clin Exp. 2024;17:352\u20138.","journal-title":"Oftalmol Clin Exp"},{"key":"1270_CR22","doi-asserted-by":"crossref","unstructured":"Picotti CSV, Fernandez Irigaray L, Morgan IG, Iribarren R. Myopia Progression in Children during COVID-19 Home Confinement in Argentina. Oftalmologia Clinica y Experimental 2021; 14: 156\u201361. https:\/\/revistaoce.com\/index.php\/revista\/article\/view\/73\/07.","DOI":"10.2139\/ssrn.3781660"},{"key":"1270_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","volume":"141","author":"MX Repka","year":"2023","unstructured":"Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141:756\u201365.","journal-title":"JAMA Ophthalmol"},{"key":"1270_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/opo.13545","author":"T Naduvilath","year":"2025","unstructured":"Naduvilath T, He X, Saunders K, Demir P, Leighton R, McCullough S, et al. Age, gender and regional\/ethnic variations in emmetropic axial growth rate. Ophthalmic Physiol Opt. 2025. https:\/\/doi.org\/10.1111\/opo.13545.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1270_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126:113\u201324.","journal-title":"Ophthalmology"},{"key":"1270_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/opo.13058","volume":"43","author":"MA Bullimore","year":"2023","unstructured":"Bullimore MA, Brennan NA. Myopia: an ounce of prevention is worth a pound of cure. Ophthalmic Physiol Opt. 2023;43:116\u201321.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1270_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/opo.12812","volume":"41","author":"P Chamberlain","year":"2021","unstructured":"Chamberlain P, Lazon de la Jara P, Arumugam B, Bullimore MA. Axial length targets for myopia control. Ophthalmic Physiol Opt. 2021;41:523\u201331.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1270_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/opo.13120","volume":"43","author":"MA Bullimore","year":"2023","unstructured":"Bullimore MA, Brennan NA, Flitcroft DI. The future of clinical trials of myopia control. Ophthalmic Physiol Opt. 2023;43:525\u201333.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1270_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2021-321005","author":"J Rappon","year":"2022","unstructured":"Rappon J, Chung C, Young G, Hunt C, Neitz J, Neitz M, et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2022. https:\/\/doi.org\/10.1136\/bjo-2021-321005.","journal-title":"Br J Ophthalmol"},{"key":"1270_CR30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","volume":"128","author":"R Saxena","year":"2021","unstructured":"Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, et al. Atropine for the treatment of childhood myopia in India: multicentric randomized trial. Ophthalmology. 2021;128:1367\u20139.","journal-title":"Ophthalmology"},{"key":"1270_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","volume":"104","author":"CSY Lam","year":"2020","unstructured":"Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104:363\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1270_CR32","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s13063-023-07696-0","volume":"24","author":"C Alvarez-Peregrina","year":"2023","unstructured":"Alvarez-Peregrina C, Sanchez-Tena MA, Martinez-Perez C, Villa-Collar C, Ohlendorf A. Clinical evaluation of MyoCare in Europe (CEME): study protocol for a prospective, multicenter, randomized, double-blinded, and controlled clinical trial. Trials. 2023;24:674.","journal-title":"Trials"},{"key":"1270_CR33","doi-asserted-by":"publisher","unstructured":"Bao J, Yang A, Huang Y, Li X, Pan Y, Ding C, Lim EW, Zheng J, Spiegel DP, Drobe B, Lu F, Chen H. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2021;106(8):1171\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318367","DOI":"10.1136\/bjophthalmol-2020-318367"},{"key":"1270_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.17116\/oftalma201913505146","volume":"135","author":"EP Tarutta","year":"2019","unstructured":"Tarutta EP, Proskurina OV, Tarasova NA, Milash SV. Markosyan GA [Long-term results of perifocal defocus spectacle lens correction in children with progressive myopia]. Vestn Oftalmol. 2019;135:46\u201353.","journal-title":"Vestn Oftalmol"},{"key":"1270_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ajo.2023.08.019","volume":"257","author":"C Yuval","year":"2024","unstructured":"Yuval C, Otzem C, Laura BS, Shirel R, Dana GN, Atalia W, et al. Evaluating the effect of a myopia control spectacle lens among children in Israel: 12-month results. Am J Ophthalmol. 2024;257:103\u201312.","journal-title":"Am J Ophthalmol"},{"key":"1270_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/aos.15649","volume":"101","author":"X Liu","year":"2023","unstructured":"Liu X, Wang P, Xie Z, Sun M, Chen M, Wang J, et al. One-year myopia control efficacy of cylindrical annular refractive element spectacle lenses. Acta Ophthalmol. 2023;101:651\u20137.","journal-title":"Acta Ophthalmol"},{"key":"1270_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10384-018-0616-3","volume":"62","author":"H Kanda","year":"2018","unstructured":"Kanda H, Oshika T, Hiraoka T, Hasebe S, Ohno-Matsui K, Ishiko S, et al. Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children: a 2-year multicenter randomized controlled trial. Jpn J Ophthalmol. 2018;62:537\u201343.","journal-title":"Jpn J Ophthalmol"},{"key":"1270_CR38","doi-asserted-by":"publisher","first-page":"M132","DOI":"10.1167\/iovs.18-25955","volume":"60","author":"JS Wolffsohn","year":"2019","unstructured":"Wolffsohn JS, Kollbaum PS, Berntsen DA, Atchison DA, Benavente A, Bradley A, et al. IMI - Clinical myopia control trials and instrumentation report. Invest Ophthalmol Vis Sci. 2019;60:M132\u201360.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1270_CR39","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.70313\/2718.7446.v17.n04.362","volume":"17","author":"LBJ Fernandez Irigaray","year":"2024","unstructured":"Fernandez Irigaray LBJ, Szeps A, Albertazzi R, Cortinez F, Lanca C, Iribarren R. Children\u2019s bedroom illumination while reading at night. Oftalmol Clin Exp. 2024;17:e516\u201322.","journal-title":"Oftalmol Clin Exp"},{"key":"1270_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2024.103857","author":"A Szeps","year":"2024","unstructured":"Szeps A, Dankert S, Saracco G, Iribarren R. A pilot study of axial length changes associated with myopia control spectacles in subjects reading under mesopic conditions. J AAPOS. 2024. https:\/\/doi.org\/10.1016\/j.jaapos.2024.103857.","journal-title":"J AAPOS"},{"key":"1270_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.11.4.17","volume":"11","author":"B Swiatczak","year":"2022","unstructured":"Swiatczak B, Schaeffel F. Transient eye shortening during reading text with inverted contrast: effects of refractive error and letter size. Transl Vis Sci Technol. 2022;11:17.","journal-title":"Transl Vis Sci Technol"},{"key":"1270_CR42","doi-asserted-by":"publisher","first-page":"21704","DOI":"10.1038\/s41598-022-26323-7","volume":"12","author":"B Swiatczak","year":"2022","unstructured":"Swiatczak B, Schaeffel F. Myopia: why the retina stops inhibiting eye growth. Sci Rep. 2022;12:21704.","journal-title":"Sci Rep"},{"key":"1270_CR43","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1055\/a-2322-9892","volume":"241","author":"B Swiatczak","year":"2024","unstructured":"Swiatczak B. Chromatic light therapy for inhibiting myopia progression: human studies. Klin Monatsbl Augenheilkd. 2024;241:1126\u20138.","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1270_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2024.108402","volume":"220","author":"F Schaeffel","year":"2024","unstructured":"Schaeffel F, Swiatczak B. Mechanisms of emmetropization and what might go wrong in myopia. Vis Res. 2024;220:108402.","journal-title":"Vis Res"},{"key":"1270_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2024.108485","volume":"224","author":"L Ingrassia","year":"2024","unstructured":"Ingrassia L, Swiatczak B, Schaeffel F. Two different visual stimuli that cause axial eye shortening have no additive effect. Vis Res. 2024;224:108485.","journal-title":"Vis Res"},{"key":"1270_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/opo.13192","author":"R Saxena","year":"2023","unstructured":"Saxena R, Gupta V, Dhiman R, Phuljhele S, Kumar P, Sharma N, et al. Effect of low-dose atropine (0.01%) on crystalline lens power among school-aged children with progressive myopia. Ophthalmic Physiol Opt. 2023. https:\/\/doi.org\/10.1111\/opo.13192.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1270_CR47","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.survophthal.2023.02.002","volume":"68","author":"J Rozema","year":"2023","unstructured":"Rozema J, Dankert S, Iribarren R. Emmetropization and nonmyopic eye growth. Surv Ophthalmol. 2023;68:759\u201383.","journal-title":"Surv Ophthalmol"},{"key":"1270_CR48","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1111\/aos.15002","volume":"100","author":"S Xiong","year":"2022","unstructured":"Xiong S, He X, Sankaridurg P, Zhu J, Wang J, Zhang B, et al. Accelerated loss of crystalline lens power initiating from emmetropia among young school children: a 2-year longitudinal study. Acta Ophthalmol. 2022;100:e968\u201376.","journal-title":"Acta Ophthalmol"},{"key":"1270_CR49","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s00417-024-06510-0","volume":"262","author":"Y Ma","year":"2024","unstructured":"Ma Y, Cao J, Yu Y, Fukuyama T, Bao Y, Ding X, et al. A Brillouin microscopy analysis of the crystalline lenses of Chinese adults with myopia. Graefes Arch Clin Exp Ophthalmol. 2024;262:3243\u201352.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1270_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/tvst.14.1.15","volume":"14","author":"TJ Gawne","year":"2025","unstructured":"Gawne TJ, Khanal S, Norton TT. An alternative mechanism for the anti-myopia effectiveness of diffusion optics technology (DOT) lenses. Transl Vis Sci Technol. 2025;14:15.","journal-title":"Transl Vis Sci Technol"},{"key":"1270_CR51","doi-asserted-by":"publisher","first-page":"26773","DOI":"10.1038\/s41598-024-78300-x","volume":"14","author":"B Swiatczak","year":"2024","unstructured":"Swiatczak B, Scholl HPN, Schaeffel F. Retinal, \u201csweet spot\u201d for myopia treatment. Sci Rep. 2024;14:26773.","journal-title":"Sci Rep"},{"key":"1270_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/opo.13426","volume":"45","author":"JA Guggenheim","year":"2025","unstructured":"Guggenheim JA, Terry L. Mechanism of optical treatments for myopia: are lenslets joining the DOTs? Ophthalmic Physiol Opt. 2025;45:337\u20139.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1270_CR53","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ophtha.2024.07.002","volume":"131","author":"B Su","year":"2024","unstructured":"Su B, Cho P, Vincent SJ, Zheng J, Chen J, Ye C, et al. Novel lenslet-ARray-integrated spectacle lenses for myopia control: a 1-year randomized, double-masked, controlled trial. Ophthalmology. 2024;131:1389\u201397.","journal-title":"Ophthalmology"},{"key":"1270_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/tvst.14.3.11","volume":"14","author":"J Neitz","year":"2025","unstructured":"Neitz J, Neitz M. The predictive and explanatory power of the contrast theory of myopia. Transl Vis Sci Technol. 2025;14:11.","journal-title":"Transl Vis Sci Technol"},{"key":"1270_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.visres.2011.12.011","volume":"55","author":"CH Chu","year":"2012","unstructured":"Chu CH, Deng L, Kee CS. Effects of hemiretinal form deprivation on central refractive development and posterior eye shape in chicks. Vis Res. 2012;55:24\u201331.","journal-title":"Vis Res"},{"key":"1270_CR56","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.visres.2009.07.011","volume":"49","author":"EL Smith 3rd","year":"2009","unstructured":"Smith EL 3rd, Hung LF, Huang J. Relative peripheral hyperopic defocus alters central refractive development in infant monkeys. Vis Res. 2009;49:2386\u201392.","journal-title":"Vis Res"},{"key":"1270_CR57","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1016\/j.visres.2006.05.008","volume":"46","author":"R Schippert","year":"2006","unstructured":"Schippert R, Schaeffel F. Peripheral defocus does not necessarily affect central refractive development. Vis Res. 2006;46:3935\u201340.","journal-title":"Vis Res"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01270-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:02:54Z","timestamp":1770454974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01270-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01270-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Abel Szeps, Martin de Tomas, Gabriel Mart\u00edn and Rafael Iribarren are consultants of NOVAR and OPULENS. Jos Rozema is a consultant for Cooper Vision. Carla Lanca reports a relationship with Eyerising that includes consulting and advisory.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by the Ethics Committee of the Argentine Society of Ophthalmology and the Government of Buenos Aires City (March 2023; Registration No. 8638). The study was also registered with the ClinicalTrials.gov Identifier Number: NCT07092072.\n                      \n                      . Patients who exhibited a myopia progression of\u2009\u2212\u20090.50 D or more within 6\u00a0months were excluded from further follow-up. As recommended by the ethics committee, these participants were transitioned to treatment with low-dose atropine. The study was conducted in accordance with the Declaration of Helsinki and its amendments, Good Clinical Practice (GCP) guidelines, and Resolution 1480\/11 of the Argentine Ministry of Health. Both parents were verbally informed about the study objectives, and written informed consent was obtained from both parents and children. Participant anonymity was strictly preserved, with all identifying information removed from the dataset prior to statistical analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}